Nedal (Nebivolol)

Nebivolol, the active ingredient in Nedal, is a beta blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension in adult patients and works by selectively blocking β1‑adrenergic receptors while enhancing nitric‑oxide mediated vasodilation, thereby helping to lower blood pressure.

GNH USA supplies Nedal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. It delivers products through its experienced network of partners.

Nebivolol is used to treat conditions within the cardiovascular disease spectrum, primarily by lowering elevated blood pressure.

- Hypertension: reduces systolic and diastolic blood pressure in adult patients. - Chronic heart failure: improves left ventricular function and may lower the risk of hospitalization in patients with reduced ejection fraction. - Cardiovascular risk reduction: contributes to overall risk management by providing vasodilatory and heart‑rate‑modulating effects.

Nebivolol may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Fatigue: general tiredness that may improve with continued use. - Nasal congestion: blockage or runny nose without infection. - Bradycardia: slower than normal heart rate, usually asymptomatic. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Symptomatic hypotension: sudden drop in blood pressure causing faintness. - Heart block: impaired electrical conduction that may need pacing. - Bronchospasm: airway narrowing, particularly in patients with asthma. - Anaphylactic reaction: rare allergic response with rash, swelling, and breathing difficulty.

Before initiating Nebivolol therapy, clinicians should consider several safety measures.

- Blood pressure monitoring: check baseline and periodic readings to assess response. - Cardiac assessment: evaluate heart rate and conduction abnormalities, especially in patients with known arrhythmias. - Asthma/COPD caution: use carefully in patients with reactive airway disease due to potential bronchospasm. - Discontinuation: avoid abrupt cessation; taper gradually to prevent rebound hypertension. - Renal/hepatic impairment: adjust dose or monitor closely in patients with organ dysfunction. - Store at room temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Nebivolol can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Other beta‑blockers: additive cardiac depression may lead to severe bradycardia. - Calcium‑channel blockers (verapamil, diltiazem): can increase plasma levels and cause heart block. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): raise Nebivolol concentrations, heightening adverse effects.

Moderate Interactions (Monitor Closely):\n- Diuretics: may potentiate hypotensive response; monitor blood pressure. - ACE inhibitors or ARBs: combined effect on blood pressure requires observation. - NSAIDs: can blunt antihypertensive effect; assess renal function. - Antidiabetic agents: may mask hypoglycemia symptoms; check glucose levels regularly.